# Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma

> **NCT02518750** · PHASE2 · TERMINATED · sponsor: **St. Jude Children's Research Hospital** · enrollment: 3 (actual)

## Conditions studied

- Acute Lymphoblastic Leukemia
- Lymphoma, Non-Hodgkin's
- Leukemia, T-Cell
- Leukemia, B-Cell

## Interventions

- **DRUG:** Dexamethasone
- **DRUG:** Panobinostat
- **DRUG:** Liposomal vincristine
- **DRUG:** Mitoxantrone
- **DRUG:** Peg-asparaginase
- **DRUG:** Bortezomib
- **DRUG:** Intrathecal Triples
- **DRUG:** High-dose methotrexate
- **DRUG:** 6-Mercaptopurine
- **DRUG:** High-dose cytarabine
- **DRUG:** Nelarabine
- **DRUG:** Cyclophosphamide
- **DRUG:** Etoposide
- **DRUG:** Clofarabine

## Key facts

- **NCT ID:** NCT02518750
- **Lead sponsor:** St. Jude Children's Research Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-11-23
- **Primary completion:** 2018-03-11
- **Final completion:** 2018-03-11
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Due to slow accrual
- **Last updated:** 2019-04-03

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02518750

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02518750, "Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT02518750. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*